Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:36 UTC
HMDB IDHMDB0014406
Secondary Accession Numbers
  • HMDB14406
Metabolite Identification
Common NameAnagrelide
DescriptionAnagrelide is only found in individuals that have used or taken this drug. It is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. [Wikipedia ]The mechanism by which anagrelide reduces blood platelet count is still under investigation. Studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. In blood withdrawn from normal volunteers treated with anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy. At therapeutic doses, anagrelide does not produce significant changes in white cell counts or coagulation parameters, and may have a small, but clinically insignificant effect on red cell parameters. Anagrelide inhibits cyclic AMP phosphodiesterase III (PDEIII). PDEIII inhibitors can also inhibit platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of anagrelide higher than those required to reduce platelet count.
Structure
Data?1582753175
Synonyms
ValueSource
AnagrelidaChEBI
AnagrelidumChEBI
BL-4162aHMDB
AgrelinHMDB
Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochlorideHMDB
6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochlorideHMDB
Anagrelide hydrochlorideHMDB
AgrylinHMDB
Chemical FormulaC10H7Cl2N3O
Average Molecular Weight256.088
Monoisotopic Molecular Weight254.996617275
IUPAC Name6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one
Traditional Nameanagrelide
CAS Registry Number68475-42-3
SMILES
ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
InChI Identifier
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
InChI KeyOTBXOEAOVRKTNQ-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as quinazolines. Quinazolines are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazanaphthalenes
Sub ClassBenzodiazines
Direct ParentQuinazolines
Alternative Parents
Substituents
  • Quinazoline
  • Aryl chloride
  • Aryl halide
  • Benzenoid
  • 3-imidazoline
  • Azacycle
  • Propargyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Organopnictogen compound
  • Organic nitrogen compound
  • Organic oxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point280 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.28 g/LNot Available
LogP2.4Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.28 g/LALOGPS
logP1.95ALOGPS
logP1.94ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)3.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.7 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity63.25 m³·mol⁻¹ChemAxon
Polarizability23.61 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+149.90230932474
DeepCCS[M-H]-147.54430932474
DeepCCS[M-2H]-181.18630932474
DeepCCS[M+Na]+156.05730932474
AllCCS[M+H]+151.332859911
AllCCS[M+H-H2O]+147.532859911
AllCCS[M+NH4]+154.932859911
AllCCS[M+Na]+155.932859911
AllCCS[M-H]-150.532859911
AllCCS[M+Na-2H]-150.232859911
AllCCS[M+HCOO]-150.032859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
AnagrelideClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl3829.6Standard polar33892256
AnagrelideClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl2357.7Standard non polar33892256
AnagrelideClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl2505.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Anagrelide,1TMS,isomer #1C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C212465.9Semi standard non polar33892256
Anagrelide,1TMS,isomer #1C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C212364.8Standard non polar33892256
Anagrelide,1TMS,isomer #1C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C213637.6Standard polar33892256
Anagrelide,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C212641.7Semi standard non polar33892256
Anagrelide,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C212589.9Standard non polar33892256
Anagrelide,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C213658.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Anagrelide GC-MS (Non-derivatized) - 70eV, Positivesplash10-05fu-6790000000-c1e9f41cee65873be06e2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Anagrelide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Anagrelide , positive-QTOFsplash10-0a4i-0490000000-03df7de701116d2d73fc2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Anagrelide 35V, Negative-QTOFsplash10-0udi-0090000000-e8b3a7f5796e22f536582021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Anagrelide 35V, Positive-QTOFsplash10-002b-0950000000-b8c3541fb23ae10e22692021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 10V, Positive-QTOFsplash10-0a4i-0090000000-d21e45412f17c227abd32016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 20V, Positive-QTOFsplash10-0a4i-0090000000-102774526a55c3c04a862016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 40V, Positive-QTOFsplash10-0079-0190000000-875bbead14cce95040962016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 10V, Negative-QTOFsplash10-0udi-0090000000-3f622f4ee02de52e01062016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 20V, Negative-QTOFsplash10-0udi-0090000000-2d627694d9ac023310742016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 40V, Negative-QTOFsplash10-0159-4290000000-e19fc941d00cc513fbea2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 10V, Positive-QTOFsplash10-0a4i-0090000000-1d28873247abf5ca835e2021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 20V, Positive-QTOFsplash10-0a4i-0090000000-1d28873247abf5ca835e2021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 40V, Positive-QTOFsplash10-00bi-0590000000-3c538f3f8332765f44962021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 10V, Negative-QTOFsplash10-0udi-0090000000-e2f0c02f41b77a097d342021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 20V, Negative-QTOFsplash10-0udi-0090000000-05fc2254e352e0a57c1a2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Anagrelide 40V, Negative-QTOFsplash10-002r-0190000000-779e8518ef504ace69bb2021-09-24Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00261 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00261 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00261
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID2097
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkAnagrelide
METLIN IDNot Available
PubChem Compound2182
PDB IDNot Available
ChEBI ID142290
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [PubMed:16000354 ]
  2. Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. [PubMed:16810615 ]
  3. Voglova J, Maisnar V, Beranek M, Chrobak L: [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]. Vnitr Lek. 2006 Sep;52(9):819-22. [PubMed:17091608 ]

Enzymes

General function:
Involved in catalytic activity
Specific function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (By similarity).
Gene Name:
PDE3A
Uniprot ID:
Q14432
Molecular weight:
124978.06
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Venuti MC, Stephenson RA, Alvarez R, Bruno JJ, Strosberg AM: Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. J Med Chem. 1988 Nov;31(11):2136-45. [PubMed:2846839 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular weight:
58406.915
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]